Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 9595 | 1073 | 33.3 | 82% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 80 | 26597 | ASPERGILLOSIS//VORICONAZOLE//AMPHOTERICIN B |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | VORICONAZOLE | Author keyword | 76 | 26% | 24% | 255 |
| 2 | HYDROXYITRACONAZOLE | Author keyword | 48 | 91% | 2% | 20 |
| 3 | POSACONAZOLE | Author keyword | 43 | 32% | 11% | 113 |
| 4 | ITRACONAZOLE | Author keyword | 16 | 11% | 13% | 135 |
| 5 | SCH 56592 | Author keyword | 11 | 100% | 1% | 6 |
| 6 | GLOBAL ESTABLISHED PHARMA BUSINESS | Address | 6 | 80% | 0% | 4 |
| 7 | PFIZER CLIN UNIT | Address | 6 | 47% | 1% | 9 |
| 8 | HYDROXY ITRACONAZOLE | Author keyword | 4 | 75% | 0% | 3 |
| 9 | CAS 84625 61 6 | Author keyword | 2 | 67% | 0% | 2 |
| 10 | ITRACONAZOLE SOLUTION | Author keyword | 2 | 67% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | VORICONAZOLE | 76 | 26% | 24% | 255 | Search VORICONAZOLE | Search VORICONAZOLE |
| 2 | HYDROXYITRACONAZOLE | 48 | 91% | 2% | 20 | Search HYDROXYITRACONAZOLE | Search HYDROXYITRACONAZOLE |
| 3 | POSACONAZOLE | 43 | 32% | 11% | 113 | Search POSACONAZOLE | Search POSACONAZOLE |
| 4 | ITRACONAZOLE | 16 | 11% | 13% | 135 | Search ITRACONAZOLE | Search ITRACONAZOLE |
| 5 | SCH 56592 | 11 | 100% | 1% | 6 | Search SCH+56592 | Search SCH+56592 |
| 6 | HYDROXY ITRACONAZOLE | 4 | 75% | 0% | 3 | Search HYDROXY+ITRACONAZOLE | Search HYDROXY+ITRACONAZOLE |
| 7 | CAS 84625 61 6 | 2 | 67% | 0% | 2 | Search CAS+84625+61+6 | Search CAS+84625+61+6 |
| 8 | ITRACONAZOLE SOLUTION | 2 | 67% | 0% | 2 | Search ITRACONAZOLE+SOLUTION | Search ITRACONAZOLE+SOLUTION |
| 9 | SBECD | 2 | 67% | 0% | 2 | Search SBECD | Search SBECD |
| 10 | SYSTEMIC ANTIFUNGAL DRUGS | 2 | 67% | 0% | 2 | Search SYSTEMIC+ANTIFUNGAL+DRUGS | Search SYSTEMIC+ANTIFUNGAL+DRUGS |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | ORAL POSACONAZOLE | 81 | 80% | 5% | 51 |
| 2 | HYDROXYITRACONAZOLE | 67 | 89% | 3% | 31 |
| 3 | UK 109 496 | 48 | 61% | 5% | 51 |
| 4 | INTRAVENOUS VORICONAZOLE | 34 | 79% | 2% | 22 |
| 5 | TRIAZOLE ANTIFUNGAL AGENT | 28 | 56% | 3% | 34 |
| 6 | EXPOSURE RESPONSE RELATIONSHIP | 27 | 76% | 2% | 19 |
| 7 | SCH 56592 | 18 | 38% | 4% | 38 |
| 8 | TO ORAL SWITCH | 15 | 88% | 1% | 7 |
| 9 | CELL TRANSPLANT RECIPIENTS | 11 | 13% | 8% | 83 |
| 10 | HYDROXY METABOLITE | 10 | 63% | 1% | 10 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Voriconazole phototoxicity in children: A retrospective review | 2015 | 2 | 23 | 70% |
| Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology | 2014 | 22 | 124 | 71% |
| Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications | 2009 | 167 | 79 | 57% |
| Voriconazole-Associated Cutaneous Malignancy: A Literature Review on Photocarcinogenesis in Organ Transplant Recipients | 2014 | 13 | 30 | 57% |
| Therapeutic Drug Monitoring of Voriconazole and Posaconazole | 2011 | 27 | 34 | 88% |
| Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring | 2012 | 35 | 55 | 78% |
| Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis | 2013 | 13 | 67 | 70% |
| Triazole Antifungal Agents in Invasive Fungal Infections A Comparative Review | 2011 | 37 | 97 | 47% |
| Voriconazole: A new triazole antifungal agent | 2003 | 334 | 37 | 51% |
| Optimizing antifungal choice and administration | 2013 | 15 | 68 | 50% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | GLOBAL ESTABLISHED PHARMA BUSINESS | 6 | 80% | 0.4% | 4 |
| 2 | PFIZER CLIN UNIT | 6 | 47% | 0.8% | 9 |
| 3 | SECT INFECT DIS MED MICROBIOL IMMUNOL | 2 | 67% | 0.2% | 2 |
| 4 | MICROBIOL CLIN INFECT DIS | 2 | 43% | 0.3% | 3 |
| 5 | HOME CANC CARE SERV | 1 | 100% | 0.2% | 2 |
| 6 | NEW S WALES REFERRAL THER EUT DRUG MONITORIN | 1 | 100% | 0.2% | 2 |
| 7 | BMBF 01KN0706 | 1 | 30% | 0.3% | 3 |
| 8 | CANC NEUROSCI | 1 | 33% | 0.2% | 2 |
| 9 | EARLY CLIN EXPT MED | 1 | 23% | 0.3% | 3 |
| 10 | AFDELING ALGEMENE INWENDIGE GENEESKUNDE | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000229280 | CYP51A//ISAVUCONAZOLE//AZOLE RESISTANCE |
| 2 | 0.0000209529 | FLUCONAZOLE//FOSFLUCONAZOLE//MICRODILUTION TEST |
| 3 | 0.0000206639 | ASPERGILLOSIS//INVASIVE ASPERGILLOSIS//INVASIVE PULMONARY ASPERGILLOSIS |
| 4 | 0.0000121099 | OPTICALLY ACTIVE ANTIFUNGAL AZOLE//BIOORGAN MED CHEM//CS 758 |
| 5 | 0.0000120370 | CANDIDEMIA//CANDIDAEMIA//ANIDULAFUNGIN |
| 6 | 0.0000106342 | SCEDOSPORIUM APIOSPERMUM//PSEUDALLESCHERIA BOYDII//SCEDOSPORIUM PROLIFICANS |
| 7 | 0.0000096892 | FUSARIOSIS//INVASIVE FUSARIOSIS//DISSEMINATED FUSARIOSIS |
| 8 | 0.0000077037 | TOLNAFTATE//KETOCONAZOLE DETERMINATION//PIRIBEDIL |
| 9 | 0.0000072280 | CYP3A//COCKTAIL//MECHANISM BASED INHIBITION |
| 10 | 0.0000068330 | AMPHOTERICIN B//AMPHOTERICIN B LIPID COMPLEX//AMPHOTERICIN B COLLOIDAL DISPERSION |